GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AtriCure Inc (NAS:ATRC) » Definitions » Enterprise Value
中文

AtriCure (AtriCure) Enterprise Value

: $1,036.8 Mil (As of Today)
View and export this data going back to 2005. Start your Free Trial

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, AtriCure's Enterprise Value is $1,036.8 Mil. AtriCure's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-22.9 Mil. Therefore, AtriCure's EV-to-EBIT ratio for today is -45.23.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, AtriCure's Enterprise Value is $1,036.8 Mil. AtriCure's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.1 Mil. Therefore, AtriCure's EV-to-EBITDA ratio for today is -127.85.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, AtriCure's Enterprise Value is $1,036.8 Mil. AtriCure's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $399.2 Mil. Therefore, AtriCure's EV-to-Revenue ratio for today is 2.60.


AtriCure Enterprise Value Historical Data

The historical data trend for AtriCure's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AtriCure Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,283.81 2,354.19 3,156.05 2,019.90 1,633.41

AtriCure Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,019.90 1,897.63 2,285.10 2,017.13 1,633.41

Competitive Comparison

For the Medical Instruments & Supplies subindustry, AtriCure's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AtriCure Enterprise Value Distribution

For the Medical Devices & Instruments industry and Healthcare sector, AtriCure's Enterprise Value distribution charts can be found below:

* The bar in red indicates where AtriCure's Enterprise Value falls into.



AtriCure Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

AtriCure's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

AtriCure's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AtriCure  (NAS:ATRC) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

AtriCure's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1036.764/-22.922
=-45.23

AtriCure's current Enterprise Value is $1,036.8 Mil.
AtriCure's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.9 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

AtriCure's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=1036.764/-8.109
=-127.85

AtriCure's current Enterprise Value is $1,036.8 Mil.
AtriCure's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.1 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

AtriCure's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1036.764/399.245
=2.60

AtriCure's current Enterprise Value is $1,036.8 Mil.
AtriCure's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $399.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AtriCure Enterprise Value Related Terms

Thank you for viewing the detailed overview of AtriCure's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


AtriCure (AtriCure) Business Description

Traded in Other Exchanges
N/A
Address
7555 Innovation Way, Mason, OH, USA, 45040
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
Executives
Karl S. Dahlquist officer: Chief Legal Officer 7555 INNOVATION WAY, MASON OH 45040
Karen Prange director 1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
Maggie Yuen director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Vinayak Doraiswamy officer: Chief Scientific Officer 7555 INNOVATION WAY, MASON OH 45040
Deborah Lee Yount officer: Chief Human Resources Officer 7555 INNOVATION WAY, MASON OH 45040
Tonya Austin officer: Chief Human Resources Officer 7555 INNOVATION WAY, MASON OH 45040
Angela L Wirick officer: Chief Financial Officer 7555 INNOVATION WAY, MASON OH 45040
Mark A Collar director 382 BISHOPBRIDGE DR, CINCINNATI OH 45255
Regina E Groves director 5751 COPLEY DRIVE, SAN DIEGO CA 92111
Douglas J Seith officer: SVP of Sales and Marketing 7555 INNOVATION WAY, MASON OH 45040
Salvatore Privitera officer: VP; Product Development 7555 INNOVATION WAY, MASON OH 45040
Justin J Noznesky officer: SVP, Mktg & Business Develop 7555 INNOVATION WAY, MASON OH 45040
Deborah H Telman director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Scott William Drake director 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Sven Wehrwein director